Positions

Overview

  • Dr. Gabrielle Rocque is an Assistant Professor of Medicine in the Divisions of Hematology & Oncology and Gerontology, Geriatrics, & Palliative Care at the University of Alabama at Birmingham (UAB). She completed her undergraduate degree, medical doctorate, Internal Medicine residency, and fellowship in Hematology & Oncology at the University of Wisconsin- Madison. She also completed a Masters of Science in Public Health from UAB. She currently practices as a medical oncologist, specializing in the care of women with breast cancer.

    Dr. Rocque’s research interests include improving the quality of healthcare delivery for cancer patients with an emphasis on shared decision-making, payment reform, and provision of supportive care services to patients. She served as Medical Director a successful 2012 Center for Medicare and Medicaid Innovation Award, which focused on improving health and healthcare costs by implementing a lay navigator workforce to support cancer patients across from diagnosis through survivorship and end-of-life. She also received an American Cancer Society Mentored Research Scholar Grant to develop treatment plans aimed to enhance shared decision making for patients with metastatic breast cancer. She is active within UAB’s payment reform initiatives, and serves as the co-Director of UAB’s Oncology Care Model Steering Committee.

    Dr. Rocque has a strong interest in the interface between community oncology practices and academia. She is a former chair of the American Society of Clinical Oncology (ASCO) Measures Task Force and the ASCO Quality of Care Committee.
  • Research Overview

  • Shared decision making, value, Metastatic breast cancer, Supportive care, Payment reform
  • Principal Investigator On

  • Memorandum of Understanding with BCBSAL - Evaluating the Implementation and Impact of Navigator-delivered ePRO Home Symptom Monitoring and Management  awarded by BLUE CROSS AND BLUE SHIELD OF ALABAMA 2021 - 2025
  • Evaluating Shared Decision Making in Cancer  awarded by CANCERCARE 2019 - 2024
  • Private Grant  awarded by Genentech 2020 - 2022
  • Enhancing Shared Decision Making in Metastatic Breast Cancer  awarded by American Cancer Society, Inc. 2017 - 2022
  • Private Grant  awarded by Pfizer Pharmaceuticals 2021 - 2022
  • Evaluating Adoption and Outcomes of Early Stage Breast Cancer Clinical Trials Results in Underrepresented and Unrepresented Populations  awarded by Johnson (Robert Wood) Foundation 2019 - 2021
  • Safety Net Program Survey: Launched 07/05/2017  awarded by PATIENT ADVOCATE FOUNDATION 2019 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2017 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2019 - 2021
  • Private Grant  awarded by Genentech 2019 - 2020
  • ECOG-ACRIN NCORP Research Base -CT  awarded by ECOG-ACRIN CANCER RESEARCH GROUP 2019 - 2020
  • Variation in Cancer Centers’ End-of-Life Quality: Role of Norms  awarded by Dartmouth College 2020
  • TBCRC-AURORA US: A Prospective Biospecimen Repository in Metastic Breast Cancer  awarded by Johns Hopkins University 2020
  • Private Grant  awarded by Genentech 2017 - 2019
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC. 2018 - 2019
  • TBCRC 029_Clinical and Biological Characterization of Male Breast Cancer  awarded by Johns Hopkins University 2015 - 2019
  • Outliers - Extreme Long-term Survivors with Metastatic Breast Cancer  awarded by University of Wisconsin-Madison 2018
  • Impact Of Guideline Concordant Treatment On Cost And Health Care Utilization In Early Stage Breast Cancer Patients  awarded by UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER (SAN ANTONIO) 2017 - 2018
  • Private Grant  awarded by Genentech 2016 - 2018
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC. 2015 - 2016
  • Private Grant  awarded by PACKHEALTH 2014 - 2016
  • Investigator On

  • Lay Coach-led Early Palliative Care for Underserved Advanced Cancer Caregivers  awarded by National Cancer Institute/NIH/DHHS 2020 - 2025
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University 2020 - 2025
  • TBCRC 050 UAB 17112-A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer  awarded by Johns Hopkins University 2019 - 2024
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • Private Grant  awarded by SERMONIX PHARMACEUTICALS INC 2021 - 2024
  • A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination with Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), In Patients with Her2-Positive Metastatic Breast Cancer who have Progressed on Prior Trastuzumab and Pertuzumab: The "AVIATOR” Study  awarded by Johns Hopkins University 2019 - 2024
  • TBCRC 049 UAB 1794: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer  awarded by Johns Hopkins University 2018 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2020 - 2023
  • UAB 17127-A Phase 1b Trial of Fulvestrant, Palbociclib (CDK4/6 inhibitor) and Erdafitinib (JNJ-42756493, Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2–/FGFR-Amplified Metastatic Breast Cancer (MBC)  awarded by VANDERBILT UNIVERSITY 2019 - 2023
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2020 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2018 - 2023
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS 2019 - 2023
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2021
  • Private Grant  awarded by TESARO, INC. 2018 - 2021
  • TBCRC 037 UAB 1644:A Trial of Endocrine Response In Women with Invasive Lobular Breast Cancer.  awarded by University of Pittsburgh The 2016 - 2021
  • UAB 1761: A Randomized, Placebo-Controlled, Double-Blind, Phase II trial of Nanoparticle Albumin-Bound Paclilaxel (Nab-Paclilaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple Negative Breast Cancer.  awarded by University of Chicago 2017 - 2021
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2020 - 2021
  • Quantifying the Burden of Breast Cancer Decision Making in Older Women  awarded by American Society of Clinical Oncology 2019 - 2021
  • Harvest for Health in Older Cancer Survivors  awarded by National Cancer Institute/NIH/DHHS 2016 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2018 - 2021
  • Private Grant  awarded by EMD SERONO 2016 - 2021
  • Private Grant  awarded by Genentech 2018 - 2021
  • Private Grant  awarded by Genentech 2018 - 2021
  • UAB 1643- A Randomized Phase II Trial of Fulvestrant With or Without Ribociclib After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer  awarded by Columbia University 2016 - 2020
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2018 - 2020
  • Enabling A Paradigm Shift: A Preference-Tolerant RCT of Personalized vs Annual Screening of Breast Cancer (WISDOM)  awarded by QUANTUM LEAP HEALTH CARE 2018 - 2020
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2018 - 2020
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2014 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2019 - 2020
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2020
  • TBCRC 048 UAB 1846: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes  awarded by Johns Hopkins University 2018 - 2019
  • TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker  awarded by Johns Hopkins University 2014 - 2019
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS 2018 - 2019
  • CITY Health II - The Center for the Study of Community Health  awarded by National Center for Chronic Disease Prevention & Health Promo./CDC/DHHS 2014 - 2019
  • UAB 1326: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-Amplified but HER2 Mutant Breast Cancer  awarded by Washington University 2013 - 2019
  • UAB17127:A phase Ib trial of fulvestrant, palbociclib (CDK4/6 inhibitor) and erdafitinib (JNJ- 42756493, pan-FGFR tyrosine kinase inhibitor) in ER+/HER2–/FGFR-amplified metastatic breast cancer (MBC)  awarded by VANDERBILT UNIVERSITY 2018 - 2019
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS 2018 - 2019
  • Utilizing Multiomic Advanced Diagnostics to Identify Palbociclib Response Predictors and a Post-treatment Multiomic Signature for Patients with ER+/HER2- Metastatic Breast Cancer  awarded by THE SIDE-OUT FOUNDATION 2017 - 2019
  • Private Grant  awarded by CAREVIVE SYSTEMS, INC. 2017 - 2019
  • Private Grant  awarded by INNOCRIN PHARMACEUTICALS, INC. 2016 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2019
  • Private Grant  awarded by PHARMACYCLICS, INC. 2015 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2018
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS 2016 - 2018
  • Private Grant  awarded by TESARO, INC. 2016 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2016 - 2018
  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC. 2014 - 2018
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2018
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2018
  • Private Grant  awarded by Novartis Pharma AG 2014 - 2017
  • Private Grant  awarded by INCYTE CORPORATION 2014 - 2016
  • Private Grant  awarded by ONCOTHYREON, INC. 2015 - 2016
  • Private Grant  awarded by ARQULE 2014 - 2016
  • Health Care Innovation Challenge  awarded by Centers for Medicare and Medicaid Services/DHHS 2012 - 2015
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015
  • Education And Training

  • Doctor of Medicine, University of Wisconsin System : Madison 2007
  • University of Wisconsin Hospital & Clinics, Residency 2010
  • University of Wisconsin Hospital & Clinics, Postdoctoral Fellowship 2013
  • Full Name

  • Gabrielle Rocque